BENZODIAZEPINES (BZO)

QuickScreen™
One-Step Rapid Drug Screen Test (Cassette
type)

A
Professional, Forensic Diagnostic Test for use in the Qualitative Detection of Benzodiazepines
and their Metabolites
in Human Urine at the Sensitivity
Level of 200 ng/ml
Established
as Standard by the U.S. Department of Health and Human
Services, DOT, World Health Organization and
SAMHSA.

INTENDED
USE

For a comprehensive
discussion on drug of abuse testing including typical detection time periods
see the DRUG
TESTING FAQ

The QuickScreen™ One-Step Rapid Benzodiazepines Test is a rapid, visual,
qualitative, competitive binding immunoassay for the detection of
Benzodiazepines and Benzodiazepine metabolites in human urine. The test provides
a fast confirmation of the presence of Benzodiazepines in the
subject sample at a minimum cutoff sensitivity level of 200 ng/ml BZO, the
sensitivity level set by the National Institute on Drug Abuse and Departments of
Health and Human Services. Note: Where indicated, any positive test should be
confirmed using quantitative methods by a qualified testing laboratory.Note:
This assay provides only a preliminary analytical test
result. A more specific alternative chemical method such as high-pressure liquid
chromatography (HPLC) or Gas chromatography/mass spectrometry (GC/MS) must be used in
order to obtain a confirmed analytical result. For test situations requiring laboratory
confirmation by such methods please refer to the QuickScreen Pro At Home Test Kit. Clinical consideration and professional judgment should be applied to all
test results, particularly when preliminary positive results are indicated.

SUMMARY
AND EXPLANATION OF THE TEST

Benzodiazepines
can be insidious drugs of abuse because they are a frequently prescribed
prescription drug. They represent a broad class of central nervous system
depressants which have anxiolytic, hypnotic,
anticonvulsant and muscle relaxant effects. Chronic abuse can result in
addiction and retardive dyskinnesia. Benzodiazepines are used therapeutically to
produce sedation, induce sleep, relieve anxiety and muscle spasms and to prevent
seizures. In general, benzodiazepines act as hypnotics in high doses, as
anxiolytics in moderate doses and as sedatives in low doses. Like the
barbiturates, benzodiazepines differ from one another in how fast they take
effect and how long the effects last. Shorter acting benzodiazepines, used to
manage insomnia, include estazolam (ProSom), flurazepam (Dalmane), quazepam
(Doral), temazepam (Restoril) and triazolam (Halcyon). Benzodiazepines with
longer durations of action include alprazolam (Xanax), chlordiazepoxide
(Librium), clorazepate (Tranxene), diazepam (Valium), halazepam (Paxipam),
lorazepam (Ativan), oxazepam (Serax) and prazepam (Centrax). Abuse of
Benzodiazepines occurs primarily because of the "high" which
replicates alcohol intoxication. Approximately 50 percent of people entering
treatment for narcotic or cocaine addiction also report abusing benzodiazepines.For comprehensive information on drug
testing including typical half-life or drug detection periods see the
Drug Testing FAQ.

The QuickScreen™ One-Step Rapid Benzodiazepines Test utilizes a unique combination of monoclonal antibodies to
selectively identify Benzodiazepines and its major metabolites in urine with a high degree of
sensitivity. The test kit is a rapid, visually read screening method that does not require
special instrumentation or training.

PRINCIPLE

The QuickScreen™ One-Step Rapid Benzodiazepines Test technology incorporates a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a Benzodiazepines derivative immobilized on a porous membrane for limited antibody sites. This is the preferred scientific method for qualitative assay. In the assay procedure, urine mixes with labeled antibody-dye conjugate and migrates through test device. When Benzodiazepines levels are below
200 ng/ml (the detection cutoff sensitivity of the test) unbound antibody-dye conjugate binds to immobilized antigen conjugate in the Test Zone ("T"), producing a pink-rose colored band that indicates a negative result. Conversely, when Benzodiazepines levels are above the detection limit of
200 ng/ml, antibody-dye conjugate binds to the free drug, forming an antigen-antibody-dye complex. The complex competes with immobilized antigen conjugate in the Test Zone, preventing the development of a pink-rose colored band. Regardless of the test result, a color band is produced in the Control Zone ("C") by a non-specific sandwich dye conjugate reaction. This band serves as a built-in quality control by demonstrating antibody recognition, verifying that the reagents are chemically active, and confirming that the test was performed correctly.

Refrigerated specimens or other materials should be equilibrated to room temperature before testing.

Open the foil pouch at the notch, remove the test device, and label the device with specimen ID.

Holding the dropper vertically as shown, add
4 drops of urine into the sample well "S"
waiting 5 seconds between drops.

Observe migration, or lateral flow of the sample across the entire test
panel. Add additional sample drops if migration is not complete.

Positive results may be observed as soon as
5 minutes, depending on the concentration of
Benzodiazepines in the tested specimen. To confirm negative results, a complete
reaction time of 8-10 minutes is required. Do not interpret results after
15 minutes.

INTERPRETATION
OF TEST RESULTS:

Negative

Positive

Invalid

The
development of two lines, a control line and a test line, in the test
result window indicates a negative test screen for the targeted drug or
drug metabolite.

The
development of only one line, the control line, in the test result
window indicates a positive test screen for the targeted drug or drug
metabolite.

The
absence of a control line in the test result window indicates an invalid
test result regardless of the presence of a test line in the test result
window.

Positive.
One
(1) pink-rose band appears in the control zone and no band appears in the test zone.
A positive result indicates the Benzodiazepines level is
200 ng/ml or higher in the test urine
sample.
Negative. Two (2) pink-rose color bands appear, one in the control region and one in the test region. A negative result indicates that the Benzodiazepines level is below the detection sensitivity of
200 ng/ml. IMPORTANT: any line, no matter how faint, appearing in the test area confirms a negative test.
Invalid.
If there are no distinct color bands visible in both the test zone
and the control zone or if there is a visible band in the test zone but not in the control
zone, then the test is invalid. In this instance, re-testing of the specimen is
recommended.

The QuickScreen™ One-Step Rapid Benzodiazepines test is now available to professionals and individuals concerned with Benzodiazepines abuse.
The test is one-step, fast, self-contained, individually packaged and can be
performed any time the targeted drug use or abuse is suspected. The tests come
in order units of five (5) individual tests at a cost per single
diagnosis/screen of $4.00 for the minimum order unit. For testing situations
where sample adulteration is suspect, a Rapid
Urine Adulteration test is available.

Test
Description/Type

Quantity

Cost

QuickScreen
Benzodiazepines (BZO) Test

Five
(5) Tests

$19.90

Fifteen
(15) Tests

$45.00

Thirty
(30) Tests

$75.00

One Hundred(100) Tests

$190.00

Two HundredFifty
(250) Tests

$375.00

*If the
order buttons are absent or inoperable, please use the
pricing overview page to order.